AD-214

BIOLOGICAL3 trials

Sponsors

AdAlta Limited, Addpharma Inc.

Conditions

Chronic Kidney DiseasesGastroesophageal Reflux DiseaseInterstitial Lung Disease

Phase 1

Phase 1 Safety, Tolerability, PK & PD Study of AD-214 Administered to Healthy Volunteers

CompletedNCT04415671

AdAlta LimitedInterstitial Lung Disease

Start: 2020-06-19End: 2022-02-08Updated: 2022-05-06

A Study to Compare PK, PD and Safety of the AD-214 and AD-2141

CompletedNCT05062876

Addpharma Inc.Gastroesophageal Reflux Disease

Start: 2021-11-01End: 2022-03-29Updated: 2022-07-20

Safety, Tolerability, PK and PD Study of AD-214 Administered to Healthy Volunteers and Patients With Interstitial Lung Disease or Chronic Kidney Disease

CompletedNCT05914909

AdAlta LimitedChronic Kidney Diseases, Interstitial Lung Disease

Start: 2023-07-17End: 2024-02-09Updated: 2024-02-13